Erik C. Schimmel

1.9k citations

18 papers · 1.3k indexed · 1 hit paper · h-index 11

Pulmonary and Respiratory Medicine top 5%
Radiation top 1%
Surgery
Radiology, Nuclear Medicine and Imaging top 10%
Oncology

Co-authors: Luca Incrocci Floris J. Pos Augustinus D. G. Krol Shafak Aluwini Wendimagegn Alemayehu Ben Heijmen Wilma D. Heemsbergen P.P. van der Toorn
Topics: Prostate Cancer Treatment and Research (10 papers)Prostate Cancer Diagnosis and Treatment (9 papers)Advanced Radiotherapy Techniques (5 papers)
Cited by: Radiation Pulmonary and Respiratory Medicine Dermatology
Journals: Journal of Clinical Oncology The Lancet Oncology The Journal of Urology
Partner nations: Netherlands United States Italy

In The Last Decade

Erik C. Schimmel

16 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

2016 329 citations Luca Incrocci, Ruud C. Wortel et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Erik C. Schimmel

Since Specialization

Citations

This map shows the geographic impact of Erik C. Schimmel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik C. Schimmel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik C. Schimmel more than expected).

Fields of papers citing papers by Erik C. Schimmel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik C. Schimmel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik C. Schimmel. The network helps show where Erik C. Schimmel may publish in the future.

Co-authorship network of co-authors of Erik C. Schimmel

This figure shows the co-authorship network connecting the top 25 collaborators of Erik C. Schimmel. A scholar is included among the top collaborators of Erik C. Schimmel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik C. Schimmel. Erik C. Schimmel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma. 2021 ·Journal of Clinical Oncology ·(unknown),(unknown),Cynthia So‐Osman,Joost S.P. Vermaat,Dick Johan van Spronsen,Wouter J. Plattel,(unknown),(unknown),Josée M. Zijlstra,Harry R. Koene,Marten R. Nijziel,Erik C. Schimmel,Lara H. Böhmer,Francisca Ong,Hein P. J. Visser,(unknown),Marie José Kersten,Berthe M.P. Aleman,Flora E. van Leeuwen,Michael Schaapveld	0
2	Projected return on investment of a corporate global health programme 2019 ·BMC Public Health ·(unknown),Erik C. Schimmel,(unknown)	2
3	Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trialbreakdown → 2016 ·The Lancet Oncology ·Luca Incrocci,Ruud C. Wortel,Wendimagegn Alemayehu,Shafak Aluwini,Erik C. Schimmel,Augustinus D. G. Krol,Peter-Paul van der Toorn,(unknown),Wilma D. Heemsbergen,Ben Heijmen,Floris J. Pos	329
4	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial 2016 ·The Lancet Oncology ·Shafak Aluwini,Floris J. Pos,Erik C. Schimmel,Augustinus D. G. Krol,P.P. van der Toorn,(unknown),Wendimagegn Alemayehu,Wilma D. Heemsbergen,Ben Heijmen,Luca Incrocci	217
5	MP14-01 HYPOFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR PROSTATE CANCER: 5-YEAR ONCOLOGIC OUTCOMES OF THE DUTCH RANDOMIZED PHASE 3 HYPRO TRIAL 2016 ·The Journal of Urology ·Ruud C. Wortel,Luca Incrocci,(unknown),Erik C. Schimmel,Augustinus D. G. Krol,Peter-Paul van der Toorn,(unknown),Maarten L.P. Dirkx,(unknown),Ben Heijmen,Floris J. Pos	2
6	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial 2015 ·The Lancet Oncology ·Shafak Aluwini,Floris J. Pos,Erik C. Schimmel,(unknown),Augustinus D. G. Krol,P.P. van der Toorn,(unknown),Maarten L.P. Dirkx,Wendimagegn Alemayehu,Ben Heijmen,Luca Incrocci	122
7	Hypofractionated Versus Conventionally Fractionated Radiation Therapy for Prostate Cancer: Five-Year Oncologic Outcomes of the Dutch Randomized Phase 3 HYPRO Trial 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Luca Incrocci,Ruud C. Wortel,Shafak Aluwini,Erik C. Schimmel,Augustinus D. G. Krol,P.P. van der Toorn,(unknown),(unknown),Wendimagegn Alemayehu,Ben Heijmen,Floris J. Pos	6
8	OC-0052: Late toxicity in the randomized phase III Dutch Hypofractionation Trial for prostate cancer patients (HYPRO) 2013 ·Radiotherapy and Oncology ·(unknown),Floris J. Pos,Erik C. Schimmel,(unknown),(unknown),P.P. van der Toorn,(unknown),(unknown),Wendimagegn Ghidey,Luca Incrocci	1
9	OC-0218 ACUTE TOXICITY OF THE RANDOMIZED PHASE III DUTCH HYPOFRACTIONATION TRIAL (HYPRO) FOR PROSTATE CANCER 2012 ·Radiotherapy and Oncology ·(unknown),Floris J. Pos,(unknown),Erik C. Schimmel,(unknown),Peter-Paul van der Toorn,(unknown),(unknown),Wendimagegn Ghidey,Luca Incrocci	6
10	Depression related to (neo)adjuvant hormonal therapy for prostate cancer 2011 ·Radiotherapy and Oncology ·Julia J. van Tol‐Geerdink,J.W.H. Leer,Emile N.J.T. van Lin,Erik C. Schimmel,Peep F. M. Stalmeier	16
11	[The patient chooses for feasibility and effectiveness]. 2009 ·PubMed ·Peep F. M. Stalmeier,Julia J. van Tol‐Geerdink,Emile N.J.T. van Lin,Erik C. Schimmel,H. Huizenga,W.A.J. van Daal,J.W.H. Leer	4
12	Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas 2008 ·International Journal of Radiation OncologyBiologyPhysics ·Karen J. Neelis,Erik C. Schimmel,Maarten H. Vermeer,Nancy J. Senff,Rein Willemze,Evert M. Noordijk	109
13	Offering a Treatment Choice in the Irradiation of Prostate Cancer Leads to Better Informed and More Active Patients, Without Harm to Well-Being 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Julia J. van Tol‐Geerdink,J.W.H. Leer,Emile N.J.T. van Lin,Erik C. Schimmel,H. Huizenga,W.A.J. van Daal,Peep F. M. Stalmeier	37
14	Doctors’ and Patients’ Preferences for Participation and Treatment in Curative Prostate Cancer Radiotherapy 2007 ·Journal of Clinical Oncology ·Peep F. M. Stalmeier,Julia J. van Tol‐Geerdink,Emile N.J.T. van Lin,Erik C. Schimmel,H. Huizenga,W.A.J. van Daal,J.W.H. Leer	69
15	Do prostate cancer patients want to choose their own radiation treatment? 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Julia J. van Tol‐Geerdink,Peep F. M. Stalmeier,Emile N.J.T. van Lin,Erik C. Schimmel,H. Huizenga,(unknown),J.W.H. Leer	41
16	Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer 2006 ·Journal of Clinical Oncology ·Alexandra W. van den Belt‐Dusebout,Janine Nuver,Ronald de Wit,Jourik A. Gietema,W.W. ten Bokkel Huinink,Patrick Rodrigus,Erik C. Schimmel,Berthe M.P. Aleman,Flora E. van Leeuwen	246
17	Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Julia J. van Tol‐Geerdink,Peep F. M. Stalmeier,P.C.M. Pasker-de Jong,H. Huizenga,Emile N.J.T. van Lin,Erik C. Schimmel,J.W.H. Leer,W.A.J. van Daal	39
18	Hypofractionation in glioblastoma multiforme 2000 ·Radiotherapy and Oncology ·Maarten C.C.M. Hulshof,Erik C. Schimmel,D. Andries Bosch,Dionisio González	59

About Erik C. Schimmel

Erik C. Schimmel is a scholar working on Radiation, Hepatology and Pulmonary and Respiratory Medicine, having authored 18 papers that have together received 1.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Advanced Radiotherapy Techniques (5 papers). The work is most often cited by research in Radiation (456 citations), Pulmonary and Respiratory Medicine (759 citations) and Dermatology (98 citations). Erik C. Schimmel has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include Luca Incrocci, Floris J. Pos, Augustinus D. G. Krol, Shafak Aluwini, Wendimagegn Alemayehu, Ben Heijmen, Wilma D. Heemsbergen, P.P. van der Toorn, Ruud C. Wortel and Peter-Paul van der Toorn. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact